KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other Non-Current Liabilities (2016 - 2025)

Vertex Pharmaceuticals has reported Other Non-Current Liabilities over the past 17 years, most recently at $1.3 billion for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $1.3 billion for Q4 2025, up 25.12% from a year ago — trailing twelve months through Dec 2025 was $1.3 billion (up 25.12% YoY), and the annual figure for FY2025 was $1.3 billion, up 25.12%.
  • Other Non-Current Liabilities for Q4 2025 was $1.3 billion at Vertex Pharmaceuticals, up from $1.2 billion in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for VRTX hit a ceiling of $1.3 billion in Q4 2025 and a floor of $107.7 million in Q2 2021.
  • Median Other Non-Current Liabilities over the past 5 years was $806.4 million (2023), compared with a mean of $673.4 million.
  • Biggest five-year swings in Other Non-Current Liabilities: plummeted 43.06% in 2021 and later soared 583.41% in 2023.
  • Vertex Pharmaceuticals' Other Non-Current Liabilities stood at $303.3 million in 2021, then surged by 126.11% to $685.8 million in 2022, then increased by 27.98% to $877.7 million in 2023, then increased by 15.6% to $1.0 billion in 2024, then grew by 25.12% to $1.3 billion in 2025.
  • The last three reported values for Other Non-Current Liabilities were $1.3 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.2 billion (Q2 2025) per Business Quant data.